RVMD
Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
Article Summary
HOLD- Revolution Medicines Inc. (Nasdaq: RVMD) announced detailed results from the global randomized Phase 3 RASolute 302 clinical trial evaluating daraxonrasib, an oral RAS(ON) multi-selective inhibitor, in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC), with results presented during late-breaking Plenary Session at 2026 American Society of Clinical Oncology Annual Meeting at 3:21 p.m.
- CDT today and published in The New England Journal of Medicine.
- The late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers demonstrated unprecedented improvements in overall survival and progression-free survival compared to standard of care cytotoxic chemotherapy with or without identified tumor RAS mutation, with all primary and key secondary endpoints of the trial being met.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | -100.0% | 25% | 0.0 ptsDeclining (-100.0%) - NOT a growth stock |
| EPS Growth Next 5Y ? | 28.0% | 25% | 80.0 ptsVery Good (28.0%) - Good outlook |
| Target Price Upside ? | 16.1% | 20% | 60.0 ptsModerate Upside (16.1%) - Target: $182.86 vs Current: $157.48 |
| Gross Margin % ? | — | 15% | 40.0 ptsNo Gross Margin Data |
| Drawdown from 52-Wk High ? | 0.8% | 15% | 20.0 ptsBarely a Dip (0.8%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About RVMD
- Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.
- The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
- Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C).
- Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.